Smartphone Behavior and Epilepsy Management

NCT ID: NCT04617418

Last Updated: 2023-04-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-11-03

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this prospective cohort study smartphone behavior surrounding epileptic seizures will be quantified, using a smartphone app, in order to optimize epilepsy evaluation and treatment

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Rationale:

The unpredictability of seizures and the unclear behavioral outcomes are major concerns for people with epilepsy and may surface as increased anxiety about independence. This unpredictability is also a true obstacle in capturing and studying seizure-related neurobehavioral alterations themselves. Also, seizures often impact consciousness and thus may go unnoticed. As a result, subjective seizure diaries are unreliable. Continuous smartphone-based monitoring of behavioral output is a fast-emerging topic and proven fruitful in monitoring other neurological disease states. In the field of epilepsy, these tools are yet to be introduced.

Objective:

The investigators hypothesize that quantifying smartphone behavior will help obtain a detailed and objective behavioral map of seizures that can complement existing subjective seizure diaries and thereby improve the way epilepsy treatments are evaluated in daily practice.

Study design:

A multicentre observational prospective cohort study with at least 3 months follow-up.

Study population:

100 subjects with refractory focal epilepsy with a seizure frequency of at least one per month.

Main study parameters/endpoints:

Change in touchscreen interactions (tapping speed, texting speed, apps used, location, sleep-wake cycles) surrounding reported epileptic seizures.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

subjects with refractory focal epilepsy with a seizure frequency

The investigators will include 100 subjects with refractory focal epilepsy with a seizure frequency of at least one per month, and ask them to keep a seizure diary and use the TapCounter app for three months.

Change in touchscreen interactions

Intervention Type BEHAVIORAL

The investigators will measure the changes in touchscreen interactions using the TapCounter app by QuantActions

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Change in touchscreen interactions

The investigators will measure the changes in touchscreen interactions using the TapCounter app by QuantActions

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥ 18 years of age
* clinical diagnosis of refractory focal epilepsy meeting ILAE criteria16, 17
* supported by at least one of the following; (1) interictal EEG with epileptiform discharges, (2) epileptogenic lesion on MRI corresponding to the presumed seizure onset zone, or (3) seizure recorded during a video-EEG
* have a seizure frequency of ≥ 1 per month
* only one seizure type, or in case of multiple seizure types only seizures that correspond to one probable onset zone (e.g. focal and focal to bilateral tonic-clonic seizures)
* have daytime seizures (exclusively or both daytime and night-time seizures)
* mentally competent and with no learning disabilities
* able to keep a seizure diary including time and date (as judged by the treating physician)
* have an Android-operating smartphone
* use their phone with at least 5 distinct smartphone apps at a minimum of 5 days a week
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Leiden University

OTHER

Sponsor Role collaborator

Stichting Epilepsie Instellingen Nederland

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Roland D Thijs, MD PhD

Role: PRINCIPAL_INVESTIGATOR

Stichting Epilepsie Instellingen Nederland

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Kempenhaeghe

Heeze, North Brabant, Netherlands

Site Status RECRUITING

Stichting Epilepsie Instellingen Nederland

Heemstede, North Holland, Netherlands

Site Status RECRUITING

Maasstad ziekenhuis

Rotterdam, South Holland, Netherlands

Site Status RECRUITING

University Medical Center Utrecht

Utrecht, , Netherlands

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Arthur R van Nieuw Amerongen

Role: CONTACT

+31235588018

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Richard Lazeron, MD PhD

Role: primary

Arthur R van Nieuw Amerongen

Role: primary

+31235588018

Barbara Kuijper, MD PhD

Role: primary

Frans SS Leijten, MD, PhD

Role: primary

+31 88 75 579 89

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SB&EM

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Brain Activity in Epilepsy
NCT05307146 RECRUITING NA
Microelectrodes in Epilepsy
NCT05200455 COMPLETED NA
Human Intracranial Electrophysiology
NCT05529264 RECRUITING NA
Mainz Epilepsy Registry
NCT05267405 UNKNOWN